Part 5 of 6—Revlimid “didn’t get any better…. You just got better at making money”
Last September, the Democratic-controlled U.S. House Oversight and Reform Committee released a 45-page report focused on Celgene and Bristol Myers Squibb’s (BMS’s) nearly two dozen price increases on Revlimid from 2005, when Celgene bought the drug, through 2019. It was part of a two-year committee investigation of several leading drug manufacturers’ price increases, executive compensation, and alleged strategies to limit competition and maximize profits.
Last September, the Democratic-controlled U.S. House Oversight and Reform Committee released a 45-page report focused on Celgene and Bristol Myers Squibb’s (BMS’s) nearly two dozen price increases on Revlimid from 2005, when Celgene bought the drug, through 2019. It was part of a two-year committee investigation of several leading drug manufacturers’ price increases, executive compensation, and alleged strategies to limit competition and maximize profits.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.